Acorda Therapeutics, of Hawthorne, N.Y., appointed Lorin Randall to its board and chairman of the audit committee.
ActivBiotics Inc., of Lexington, Mass., appointed David McLachlan to its board.
Allos Therapeutics Inc., of Westminster, Colo., appointed Paul Berns president, CEO and member of its board.
Alpharma Inc., of Fort Lee, N.J., appointed Peter Tombros chairman.
Altus Pharmaceuticals Inc., of Cambridge, Mass., appointed Harry Penner to its board and audit committee.
Amarillo Biosciences Inc., of Amarillo, Texas, appointed Gary Coy chief financial officer.
Amarin Corp. plc, of London, appointed John Climax nonexecutive director.
Amicus Therapeutics, of Cranbury, N.J., appointed Donald Hayden executive chairman.
Amylin Pharmaceuticals Inc., of San Diego, appointed Steven Altman to its board.
Anadys Pharmaceuticals Inc., of San Diego, hired Carol Gallagher as vice president, commercial affairs.
AtheroGenics Inc., of Atlanta, appointed Walker Anderson Long vice president of clinical research.
Atrium Biotechnologies Inc., of Quebec City, appointed Yves Julien to its board.
Avigen Inc., of Alameda, Calif., appointed Drew Jones senior director of clinical affairs, and Michael Hensley head of the company's regulatory affairs. It also elected Richard Wallace to its board.
Biogen Idec Inc., of Cambridge, Mass., named David Parkinson senior vice president, oncology research and development, and promoted John Cox to general manager and vice president of manufacturing of its Research Triangle Park, N.C., facility.
Bionovo Inc., of Emeryville, Calif., appointed Frances Preston to its board.
BioSyntech Inc., of Laval, Quebec, appointed Joseph Benarrosh chairman.
Callisto Pharmaceuticals Inc., of New York, appointed Arthur Sytkowski clinical trial adviser and medical safety monitor.